Company profile: GenSight Biologics
1.1 - Company Overview
Company description
- Provider of gene therapy-based treatments for retinal degenerative diseases. Develops candidates such as GS010 (lenadogene nolparvovec) for Leber Hereditary Optic Neuropathy (LHON) and GS030, an optogenetics-based therapy in Phase I/II trials, leveraging mitochondrial targeting sequence (MTS) technology and optogenetics.
Products and services
- Gene Therapy: Engineers therapeutic-grade interventions that modify or manipulate genes to treat or prevent retinal degenerative diseases, enabling targeted genetic modulation with disease-specific applications
- GS010 (lenadogene nolparvovec): Clinical-stage, gene therapy product engineered to treat Leber Hereditary Optic Neuropathy (LHON) through gene modulation, presently under clinical development
- GS030: Optogenetic-enabled, gene therapy product in Phase I/II clinical trials, created to address retinal degenerative diseases by using light to control genetically modified cells expressing light-sensitive ion channels
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to GenSight Biologics
Frugi Bio
HQ: United States
Website
- Description: Provider of modular, paper-based, secure diagnostics for viral outbreak management using synthetic biology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Frugi Bio company profile →
XyloCor Therapeutics
HQ: United States
Website
- Description: Provider of gene therapies for coronary artery disease: XC001 treats refractory angina by stimulating new coronary blood vessel formation; XC002 is in development to regenerate cardiac tissue in heart failure after past heart attacks by converting non-functioning cardiac cells into functioning ones.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full XyloCor Therapeutics company profile →
Gateway Genomics
HQ: France
Website
- Description: Provider of genetically based tests for families and cancer care, including SneakPeek Early Gender Test to determine fetal sex from a small maternal blood sample as early as six weeks; Foresight Carrier Screen for inherited conditions; Prequel Prenatal Screen to identify risk of chromosomal conditions like Down syndrome from week 10; and oncology tests Prolaris and Precise to assess prostate cancer aggressiveness and tumor variants to guide treatment decisions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gateway Genomics company profile →
Mirati Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology, based at 9363 Towne Centre Dr, San Diego, CA, United States.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mirati Therapeutics company profile →
Immuneering
HQ: United States
Website
- Description: Provider of bioinformatics-driven drug discovery developing investigational medicines, including IMM-1-104 targeting RAS-mutant advanced solid tumors with once-daily oral dosing, and IMM-6-415, a Deep Cyclic Inhibitor for RAF or RAS-mutant advanced solid tumors with twice-daily dosing; also maintains an Expanded Access Policy (not currently available).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immuneering company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for GenSight Biologics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to GenSight Biologics
2.2 - Growth funds investing in similar companies to GenSight Biologics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for GenSight Biologics
4.2 - Public trading comparable groups for GenSight Biologics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →